Drug Trial Radar · NCT05430919
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Aug 15, 2022
Primary completion
Jul 31, 2023
Study completion Jul 31, 2023
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jun 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU) challenge in participants receiving REGN5713-5714-5715 versus placebo (Part A)
Conditions
- Allergic Rhinitis
- Conjunctivitis
Interventions
REGN5713Drug
Administered subcutaneously (SC)
REGN5714Drug
Administered SC
REGN5715Drug
Administered SC
PlaceboOther
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Total Nasal Symptom Score (TNSS) (2 to 6 Hours) During Out-of-season Birch Allergen Environmental Exposure Unit (EEU) Challenge (REGN5713-5714-5715 vs. Placebo) at Day 29Time frame: Day 29 from randomization (Out-of-season)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Kingston General Health Research Institute
Kingston, Ontario, Canada
Inflamax Research Limited DBA Cliantha Research
Mississauga, Ontario, Canada
Clinique Specialisee en Allergie de la Capitale
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.